PRO-LAD

Active seizure disorder or epilepsy. Serotonergic psychedelics may reduce seizure threshold, though direct evidence is limited. Risk is significantly amplified by concurrent lithium or tramadol use.

Bipolar I disorder, particularly with history of psychotic features, represents an absolute contraindication. Bipolar II carries elevated risk. Serotonergic psychedelics can destabilize mood cycling and precipitate mania.

Personal or family history of schizophrenia, schizoaffective disorder, or other psychotic spectrum disorders. 5-HT2A agonists can trigger acute psychosis or prolonged psychiatric destabilization in predisposed individuals. This is the most consistently documented psychiatric risk of the serotonergic psychedelic class.

No reproductive or developmental toxicity data exist for PRO-LAD. Ergoline-class compounds have theoretical uterotonic potential. Contraindicated during pregnancy and breastfeeding as a standard precaution.

Concurrent lithium use is an absolute contraindication. The LSD + lithium combination is associated with seizures in case reports. This risk extends to PRO-LAD by class analogy as a 5-HT2A agonist lysergamide.

Concurrent tramadol use presents dual risk: serotonin syndrome from combined serotonergic load, and compounded seizure threshold reduction. Classified as dangerous interaction.

Concurrent use of monoamine oxidase inhibitors (MAOIs) potentiates serotonergic activity and presents serotonin syndrome risk. Both irreversible (phenelzine, tranylcypromine) and reversible (moclobemide) MAOIs are contraindicated.